Stereotactic Body Radiation Therapy for Kidney Cancer

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Yale University, New Haven, CTKidney Cancer+3 MoreStereotactic Body Radiation Therapy - Radiation
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trialwill test if radiation therapy helps treat metastatic renal cancer in patients using an immune checkpoint inhibitor.

Eligible Conditions
  • Kidney Cancer
  • Oligoprogressive
  • Progression

Treatment Effectiveness

Study Objectives

1 Primary · 3 Secondary · Reporting Duration: Up to two years

6 Months
Progression Free Survival
Up to two years
Overall survival
Rate of Response
Recurrence

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Side Effects for

Treatment (Chemotherapy, Oregovomab, SBRT, Surgery)
55%Leukopenia
36%Thrombocytopenia
36%Lymphopenia
18%AST elevation
18%ALT elevation
18%Anemia
18%Reduced ANC
9%Sinusitis
9%Pneumonia
9%Pancreatitis
9%Hyperkalemia
9%Urinary tract infection
9%Sepsis
9%Pleural effusion
9%Acidosis
9%Cardiac disorders
9%Orthostasis
9%Rash
9%Nausea
9%Vomiting
9%Dehydration
9%Depression
9%Somnolence
9%Hypokalemia
This histogram enumerates side effects from a completed 2018 Phase 2 trial (NCT01959672) in the Treatment (Chemotherapy, Oregovomab, SBRT, Surgery) ARM group. Side effects include: Leukopenia with 55%, Thrombocytopenia with 36%, Lymphopenia with 36%, AST elevation with 18%, ALT elevation with 18%.

Trial Design

1 Treatment Group

Stereotactic Body Radiation Therapy
1 of 1

Experimental Treatment

30 Total Participants · 1 Treatment Group

Primary Treatment: Stereotactic Body Radiation Therapy · No Placebo Group · Phase 2

Stereotactic Body Radiation Therapy
Radiation
Experimental Group · 1 Intervention: Stereotactic Body Radiation Therapy · Intervention Types: Radiation
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Stereotactic Body Radiation Therapy
2019
Completed Phase 2
~650

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to two years

Who is running the clinical trial?

Yale UniversityLead Sponsor
1,705 Previous Clinical Trials
20,476,073 Total Patients Enrolled
Kimberly Johung, MDPrincipal InvestigatorYale University

Eligibility Criteria

Age 18+ · All Participants · 12 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are expected to live for at least 6 more months.

Frequently Asked Questions

Do you have any open recruitment spots for this trial?

"Affirmative, according to clinicaltrials.gov this study is still recruiting volunteers. The recruitment effort was initiated on August 8th 2022 and recently updated on December 6th of the same year. 30 participants are needed at a single medical facility." - Anonymous Online Contributor

Unverified Answer

What risks have been associated with Stereotactic Body Radiation Therapy?

"Our team at Power rated Stereotactic Body Radiation Therapy's safety a 2 since the trial is in Phase 2, which provides evidence of its security but no proof that it works." - Anonymous Online Contributor

Unverified Answer

What is the enrollment size of this clinical trial?

"Affirmative, the information available on clinicaltrials.gov reflects that this study is actively recruiting participants; first posted in August 2022 and last updated December 6th of the same year. To complete the trial, 30 patients are needed at one site only." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.